Mustang Bio Inc (NASDAQ:MBIO)

0.476
Delayed Data
As of Sep 30
 +0.0086 / +1.84%
Today’s Change
0.42
Today|||52-Week Range
2.65
-71.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$50.0M

Company Description

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Contact Information

Mustang Bio, Inc.
377 Plantation Street
Worcester Massachusetts 01605-2245
P:(781) 652-4500
Investor Relations:

Employees

Shareholders

Other institutional9.90%
Mutual fund holders6.97%
Individual stakeholders11.32%

Top Executives

Manuel LitchmanPresident, Chief Executive Officer & Director
Eliot M. LurierChief Financial Officer
Knut NissChief Technology Officer
Bruce DezubeSenior Vice President & Head-Clinical Development
Susan E. WardVice President-Clinical Operations